Scholarlink

<p>To report the results of Endpoint Management (EpM) with PASCAL laser in the treatment of chronic central serous retinopathy (CSR). A 577&#xa0;nm yellow laser was applied using PASCAL with EpM to 11 eyes on 11 patients who were followed for CSR for at least 12 months in this prospective study. The laser spot size was set to 200&#xa0;μm, the pulse duration was 15 msec, and the spot spacing was set to 0.25 diameter. In cases where recurrence was present or subretinal fluid did not disappear, the laser was applied again three months after the last laser treatment. Detailed anterior segment and fundus examination, intraocular pressure measurement, and optical coherence tomography (OCT) were performed. Fundus fluorescein angiography (FFA) was performed at the time of diagnosis and at the end of the 6th month. The treatment was applied once for four patients (38.3%), two times for five patients (45.4%), three times for one patient (9.1%), and five times for one patient (9.1%) to achieve these results. The average pre-laser central macular thickness (CMT) value was 343.3 ± 50.2&#xa0;μm, and post-treatment, the CMT value decreased to 233.1 ± 20.3&#xa0;μm (<i>p</i> = 0.008). According to baseline examinations, the patients’ mean pre-treatment BCVA (logMAR) value was 0.46 ± 0.18, which improved to 0.34 ± 0.31 with treatment (<i>p</i> = 0.012). Five patients (45.4%) had retinal pigment epithelial changes, and no other patients had complications. PASCAL with EpM using a 577&#xa0;nm yellow laser is an effective and reliable treatment for patients with chronic CSR. The frequency of retinal pigment epithelial change was higher than in other studies in the literature in our study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The results of subthreshold 577 nm yellow laser application using pascal laser system in patients with chronic central serous chorioretinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月9日

查看全文
  • Mehmet Önen,
  • Kürşad Ramazan Zor,
  • Levent Doğan,
  • Erkut Küçük,
  • Gamze Yıldırım Biçer,
  • Ömer Özer

摘要

To report the results of Endpoint Management (EpM) with PASCAL laser in the treatment of chronic central serous retinopathy (CSR). A 577 nm yellow laser was applied using PASCAL with EpM to 11 eyes on 11 patients who were followed for CSR for at least 12 months in this prospective study. The laser spot size was set to 200 μm, the pulse duration was 15 msec, and the spot spacing was set to 0.25 diameter. In cases where recurrence was present or subretinal fluid did not disappear, the laser was applied again three months after the last laser treatment. Detailed anterior segment and fundus examination, intraocular pressure measurement, and optical coherence tomography (OCT) were performed. Fundus fluorescein angiography (FFA) was performed at the time of diagnosis and at the end of the 6th month. The treatment was applied once for four patients (38.3%), two times for five patients (45.4%), three times for one patient (9.1%), and five times for one patient (9.1%) to achieve these results. The average pre-laser central macular thickness (CMT) value was 343.3 ± 50.2 μm, and post-treatment, the CMT value decreased to 233.1 ± 20.3 μm (p = 0.008). According to baseline examinations, the patients’ mean pre-treatment BCVA (logMAR) value was 0.46 ± 0.18, which improved to 0.34 ± 0.31 with treatment (p = 0.012). Five patients (45.4%) had retinal pigment epithelial changes, and no other patients had complications. PASCAL with EpM using a 577 nm yellow laser is an effective and reliable treatment for patients with chronic CSR. The frequency of retinal pigment epithelial change was higher than in other studies in the literature in our study.